(Q37763106)

22 August 2017

1 reference

title

Optimizing outcomes in patients with chronic myeloid leukemia in chronic phase: comparative safety profiles of newer agents (English)

1 reference

22 August 2017

main subject

chronic myeloid leukemia

0 references

author name string

Kevin Kelly

1

1 reference

22 August 2017

Ronan Swords

2

1 reference

22 August 2017

Devalingam Mahalingam

3

1 reference

22 August 2017

Francis J Giles

4

1 reference

22 August 2017

publication date

1 August 2010

1 reference

22 August 2017

1 reference

22 August 2017

volume

51

1 reference

22 August 2017

issue

8

1 reference

22 August 2017

page(s)

1399-1413

1 reference

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.491135

Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.491135

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.491135

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.491135

Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.491135

Congestive heart failure is a rare event in patients receiving imatinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.491135

Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.491135

Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.491135

Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.491135

Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.491135

Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.491135

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.491135

In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.491135

Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.491135

Overriding imatinib resistance with a novel ABL kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.491135

An efficient rapid system for profiling the cellular activities of molecular libraries.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.491135

2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (d

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.491135

Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.491135

Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.491135

Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.491135

Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.491135

Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.491135

Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.491135

Bench to bedside: BRCA: from therapeutic target to therapeutic shield

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.491135

The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.491135

PDGF receptors as targets in tumor treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.491135

Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.491135

The SRC family protein tyrosine kinase p62yes controls polymeric IgA transcytosis in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.491135

Cellular functions regulated by Src family kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.491135

A novel role for FAK as a protease-targeting adaptor protein: regulation by p42 ERK and Src.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.491135

Calpain: a role in cell transformation and migration

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.491135

In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.491135

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.491135

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.491135

Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.491135

The new tyrosine-kinase inhibitor and anticancer drug dasatinib reversibly affects platelet activation in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.491135

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.491135

Tasigna for chronic and accelerated phase Philadelphia chromosome--positive chronic myelogenous leukemia resistant to or intolerant of imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.491135

Pancreatic enzyme elevation in chronic myeloid leukemia patients treated with nilotinib after imatinib failure

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.491135

Benign pancreatic hyperenzymemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.491135

Impaired fasting glucose level as metabolic side effect of nilotinib in non-diabetic chronic myeloid leukemia patients resistant to imatinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.491135

STI571: targeting BCR-ABL as therapy for CML.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.491135

Management of drug toxicities in chronic myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.491135

Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon alfa

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.491135

Src family tyrosine kinases and growth factor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.491135

Role of the KIT protooncogene in normal and malignant human hematopoiesis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.491135

The biology of stem cell factor and its receptor C-kit

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.491135

Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.491135

Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.491135

Overcoming resistance in chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.491135

Crystal structure of the T315I Abl mutant in complex with the aurora kinases inhibitor PHA-739358

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.491135

Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.491135

Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.491135

Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimizati

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.491135

Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.491135

Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.491135

Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.491135

Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.491135

Pleural Effusion in Patients With Chronic Myelogenous Leukemia Treated With Dasatinib After Imatinib Failure

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.491135

Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response o

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.491135

Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.491135

UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2010.491135

10.3109/10428194.2010.491135

21 January 2018

Identifiers

DOI

1 reference

22 August 2017

1 reference